Drugs / Euvax B®
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01867463 | Mar 2013 → Dec 2015 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02697474 | Feb → Jun 2016 | hepatitis B virus infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT06800131 Comparator | Feb 2025 → Aug 2026 overdue | hepatitis B virus infection | International Vaccine Institute | Not yet recruiting | No outcome recorded |
| — | NCT03193775 Comparator | Aug 2011 → Oct 2015 | chronic hepatitis B virus infection | Zagazig University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Euvax B | “HBV vaccine which contains Purified HBsAg produced by recombinant DNA technology (Euvax-B, LG Life sciences, Korea)” NCT03193775 ↗4“Euvax B™ (LG Chemical) is a white, slightly opalescent suspension.” NCT06800131 ↗ “Euvax B®” NCT02697474 ↗ |
| Modality | Vaccine | “Euvax B (comparator vaccine)” PMID 30061051 ↗ Jul 2018 |
| Route | Intramuscular | “0.5 mL, Intramuscular” NCT02697474 ↗ |